abbv-3373
mAbexperimentalADC
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Mar 27, 2019 (NCT03823391)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- TNF-alphaBINDING AGENT
TNF-alpha binding agent
- TNF-alphaINHIBITOR
TNF inhibitor
- Glucocorticoid receptorMODULATOR
Glucocorticoid receptor modulator
Chemistry & pharmacology
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
- Payload
- Unclear
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297572 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03823391 | Phase 1 | Mar 27, 2019 | AbbVie |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AbbVie | For profit | 1 | 1 | 1 | 2019 |
1 organizations
Page 1 / 1